Mar 3, 2017
Over the past decade, great strides have been made in the understanding of the pathobiology of pulmonary vascular disease, and from these findings new therapeutic options have emerged. It is increasingly clear that pulmonary vascular pathology is integral to a number of childhood disorders.
At the 11th International Conference Neonatal & Childhood Pulmonary Vascular Disease, chair's Jeffrey R. Fineman, MD and Ian Adatia, MBChB, FRCP will bring together international experts to explore their current understanding of the basic pathobiology as well as new and future therapies for neonatal, pediatric, and adult pulmonary vascular diseases. Learn more here.
Jeff:
My name's Jeff Fineman. I'm originally from New York, where I did
most of my medical school training, and then I moved out here to
University California San Francisco, where I trained in pediatric
critical care medicine. I started my research career at the
Cardiovascular Research Institute here. I do ICU for a living,
predominantly cardiac ICU. I run the ICU here at UCSF Benioff
Children's Hospital. I'm also now a senior investigator at the
Cardiovascular Research Institute.
Ian:
My name's Ian Adatia, and I'm professor of pediatrics at the
University of Alberta. I'm director of the Pediatric Pulmonary
Hypertension Service at the Stollery Children's Hospital in
Edmonton, Alberta.
Jeff:
It was kind of the golden years for me, because I was up and going
in the lab, kind of independently, and then Ian came. I really saw
an expert at the bedside and clinical researcher, a human-based
researcher in Ian. I had really been more of a basic science
researcher. It was really a great time, and I felt like I couldn't
get enough time together to talk about problems, etc. It came up
one day that we should really put together a conference focused on
neonatal and pediatric cardiovascular disease.
Ian:
It's hard to imagine it's been a decade of organizing the
conference with Jeff. It's been a real pleasure, actually, to work
with Jeff. It's been a really good partnership. I think Jeff
recognized that we didn't have a conference dedicated to the
science and clinical care of children, and adolescents, and babies
with pulmonary hypertension. He wanted to bring together clinicians
and scientists to one venue where they would be free to discuss for
two days, and interact for two days, and come up with ideas that
might be beneficial.
Jeff:
We started adding a science session for particularly young
investigators can come and present their work. That's really taken
off. We've added some awards for young investigators, a basic
science award and a clinical science award. That's been very
nice.
Ian:
One of the most important milestones was when we started to try to
include children and families, get money for them to travel, and
have a special family-oriented sessions so that the families could
meet the physicians and the scientists, and give their point of
view both formally and informally. In that way, I think it's become
a really fulfilling conference for the scientists, the clinicians,
and the families and the children.
Jeff:
One of the big focuses of Ian and I over the last few years is
really to try to build up a family session, a session where
families, and patients, and siblings, things that are really
focused on the needs of families from pediatric pulmonary vascular
disease, a place for them to come and talk amongst themselves, and
also, hopefully we can put together a program that's useful for
them.
Ian:
Going forward, we'd really like to have more funding for families
and children to come, and take part in the meeting, and really,
really express their opinion, and interact with the scientists and
clinicians, because I think that's the way for us to move
forward.
Jeff:
It's really a passion of ours. It's not something that is
financially feasible, because we don't charge the families, nor
should we, but it's something that we think is really important. I
really think there's a void, in a place where they can all come in
a formal setting and learn from each other. This would be the
perfect place to do that. We do it in parallel with the science
session. It's the only time when there's two sessions running
simultaneously, and we want both of those areas to really build. We
have the junior people, the junior investigators and the young
pulmonary hypertension experts of the next generation, a place to
foster them, and also, a place to support families and their
patients.
Ian:
All our decisions are very important for the families, and that we
have such a huge responsibility to them, and that when they're
present, it makes you think about what's being said at the meeting.
For instance, when people talk about mortality, and there's a
family there, it changes your perception of that word, and how it's
felt, and what it means, and I think inspires people to really work
harder, do more, and try to find an answer for pulmonary vascular
disease. The stories that the families and children have told have
been inspiring. It's something that you don't have time in clinic
to listen to, and you don't always realize how articulate and how
intelligent the families and the patients are about their disease,
and what a lot you can learn from them. Just because of the
pressures of everyday clinic life, it's hardly time to get
everything done in a day. To come into a meeting like this really
helps you to step back and hear what they have to say, listen to
their reactions, where they want to go.
Jeff:
Every year, it's gotten more and more popular. We'll keep going,
trying to make it an important part of the meeting.
Learn more about pulmonary hypertension at phaware365.global. Never miss an episode with the phaware® podcast app. Follow us @phaware on facebook, twitter, instragram, youtube & linkedin #phaware #phawareMD